Company / Revenue
KIORA PHARMACEUTICALS INC Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$16.0M
FY2025
5-year range
$0 / $16.0M
FY2021-FY2025
Trend
-
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue returned to growth in FY2025 after 2 years of decline, reaching $16M.
Based on SEC 10-K filings.
$16M in FY2025 with a 5-year CAGR of +42.9%.
Improved from $12,059 to $16M over the past 4 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +42.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +42.9%, indicating consistent growth.
- Lowest revenue in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -5.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $16.0M | - |
| FY2024 | $0 | -100.0% |
| FY2021 | $12.1K | -99.6% |
| FY2020 | $2.7M | +62.5% |
| FY2019 | $1.7M | +305.5% |
| FY2018 | $407.5K | -39.1% |
| FY2017 | $669.3K | - |
| FY2016 | $0 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026